-plc-logo-1200x675.png?v=20220316072908){kind=logo}
Shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBP – Get Free Report) were up 30.7% during trading on Tuesday . The stock traded as high as $9.43 and last traded at $7.28. Approximately 4,306,304 shares traded hands during trading, an increase of 1,545% from the average daily volume of 261,799 shares. The stock had previously closed at $5.57.
TC Biopharm Price Performance
The business’s 50 day simple moving average is $6.50 and its 200 day simple moving average is $10.71. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 1.31.
TC Biopharm Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.
Recommended Stories
- Five stocks we like better than TC Biopharm
- What is a Stock Market Index and How Do You Use Them?
- 3 Small Cap Stocks That Insiders Are Buying
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
